Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 31.92 USD -0.78% Market Closed
Market Cap: 1.8B USD

Wall Street
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 33.02 USD with a low forecast of 24.24 USD and a high forecast of 40.95 USD.

Lowest
Price Target
24.24 USD
24% Downside
Average
Price Target
33.02 USD
3% Upside
Highest
Price Target
40.95 USD
28% Upside
Stoke Therapeutics Inc Competitors:
Price Targets
688180
Shanghai Junshi Biosciences Co Ltd
24% Downside
COV
Covalon Technologies Ltd
71% Upside
RARE
Ultragenyx Pharmaceutical Inc
145% Upside
IKT
Inhibikase Therapeutics Inc
186% Upside
ADCT
ADC Therapeutics SA
132% Upside
QTTB
Homology Medicines Inc
261% Upside
DTIL
Precision BioSciences Inc
684% Upside
EXEL
Exelixis Inc
0% Downside

Revenue
Forecast

Revenue Estimate
Stoke Therapeutics Inc

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 4 years is 21%.

N/A
Past Growth
21%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STOK's stock price target?
Price Target
33.02 USD

According to Wall Street analysts, the average 1-year price target for STOK is 33.02 USD with a low forecast of 24.24 USD and a high forecast of 40.95 USD.

What is Stoke Therapeutics Inc's Revenue forecast?
Projected CAGR
21%

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 4 years is 21%.

Back to Top